SCHEMBL803659

SCHEMBL803659

COC(=O)c1ccc2c(c1)/C(=N/O)CCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.44
ALDH1A1 P00352 4/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
KDM4E B2RXH2 3/20 0.41
CASP3 P42574 2/20 0.41
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SENP7 Q9BQF6 1/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670311 0.82 GRM5 (0.47) CYP2C9ALDH1A1TSHRLMNAMAPK1
SCHEMBL29446216 0.82 GRM5 (0.47) CYP2C9ALDH1A1TSHRLMNAMAPK1
SCHEMBL11540789 0.77 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2KDM4ERAB9A
SCHEMBL14682173 0.77 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2KDM4ERAB9A
SCHEMBL11540786 0.77 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2KDM4ERAB9A
SCHEMBL803507 0.77 MAPK14 (0.44) ALDH1A1LMNASMN1; SMN2KDM4ECASP3
SCHEMBL13131193 0.77 MAPK14 (0.44) ALDH1A1LMNASMN1; SMN2KDM4ECASP3
SCHEMBL31417661 0.77 PRKCI (0.57) CYP2C9ALDH1A1TSHRLMNAMAPK1
SCHEMBL3490016 0.77 PRKCI (0.57) CYP2C9ALDH1A1TSHRLMNAMAPK1
SCHEMBL2260234 0.77 SMN1; SMN2 (0.46) CYP2C9ALDH1A1TSHRLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 CYP2C9 1322/4885ALDH1A1 1267/4885TSHR 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.